Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.
about
HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practiceNext-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneityPerspectives on new biomarkers in gastric cancer: diagnostic and prognostic applicationsTrastuzumab in the management of gastroesophageal cancer: patient selection and perspectivesThe genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyondA first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumorsOptimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumabAbsolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue.Primary and acquired resistance to biologic therapies in gastrointestinal cancers.Clinical impact of tumour biology in the management of gastroesophageal cancerRecent advances in the HER2 targeted therapy of gastric cancerReproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off ruleMass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH.Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplificationCytogenomic profiling of breast cancer brain metastases reveals potential for repurposing targeted therapeutics.Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens.A HER2-specific Modified Fc Fragment (Fcab) Induces Antitumor Effects Through Degradation of HER2 and Apoptosis.A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology.Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China.Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy.Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithmQuantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives.The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.Investigational therapies targeting the ErbB family in oesophagogastric cancer.Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.Update on Gastroesophageal Adenocarcinoma Targeted Therapies.A novel non-ATP competitive FGFR1 inhibitor with therapeutic potential on gastric cancer through inhibition of cell proliferation, survival and migration.Molecular pathology in real time.Perspectives of HER2-targeting in gastric and esophageal cancer.Novel Targeted Therapies for Esophagogastric Cancer.Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.Low expression of fibulin-1 correlates with unfavorable prognosis in gastric cancer.Targeted therapies for gastric cancer: failures and hopes from clinical trialsGene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method.Pathological complete response and long-term survival in a very elderly patient after neoadjuvant chemotherapy for locally advanced, unresectable gastric cancer.
P2860
Q26741253-507E49E6-F52D-4A96-9E8C-2ECEF2A6EBE0Q26992272-EB0041A3-8420-4C36-A21F-A34DBE127D0FQ27012898-6405D1FC-3BA7-44A4-B719-560A222F91C3Q28077666-573E2E46-E195-4342-9661-57545FC96D6EQ28078788-8321E8FA-1864-45A4-B03C-5BE2E3757A26Q33424270-E753339D-B615-4B32-B848-4CC532E2457FQ33429869-09D720DA-812C-4189-A6AF-DFAABA5BF6F1Q33688421-5E34B81D-74A4-4BF4-858B-8308D975DDB8Q33761681-B270D7FC-C32F-454C-957A-020AB1D10DECQ33830522-7922265E-EAE1-4181-8325-F8F281147DC5Q33895573-BEC625B8-6F29-426F-89CA-43309D9ED595Q33922534-FE12751D-D9B0-4959-8F0E-31AFC2B26103Q34967104-10ED8322-809A-4261-8C5C-AFBB665A1C52Q35525379-1E95D3DB-9531-435F-B81C-7FE599DDFE95Q35845600-AC2B4B38-AA66-431F-8DAB-C6B57CA92631Q35863066-5AD52D24-EF6A-4964-812D-5CF2335EC722Q35987423-A7EE36CA-BF69-49CE-BC3E-32A833661DCDQ36102672-80EFC26F-F319-4638-BF34-4D170E3B70ECQ36546068-ABEB05FE-6DA5-43AB-8A12-363BABF49285Q36757173-61188333-0765-445B-BD00-A8A018EEAC3BQ36832238-3048E7F7-E4BD-424E-A3B0-F1F12721CAC6Q37012387-533A43FE-41E2-412A-8DA7-14F0091D26E2Q37644205-27B459E1-3596-4561-BB04-EB7A5B0DD037Q37687784-1BF7DE77-323B-44DC-A1F8-E9D0ABBAA1A2Q37735589-956F9733-AFF0-4F39-B813-30BC9F3C52EDQ38209464-AA7091E0-8BB1-4D70-9E28-9DB3EA059A22Q38210070-374334E0-BEA4-4350-80F9-4EA55E038E1AQ38221886-614705F4-E355-4C13-9C62-0C3219069BFBQ38384113-6FF3038B-488E-48C3-A54F-7C53B286B132Q38661973-70607829-2149-4A91-AF83-B775BF11FF68Q38684349-11E89F37-7B57-4375-95E9-7FF747BDCBBFQ38711736-67A4D654-6196-4924-AD56-C32B013F6784Q38756841-126F9644-C1AF-4955-BBF6-4422D99E8A5DQ38848389-78740B9F-E9D5-4140-A3E1-DBDE64E88BA5Q39171565-9BCC15BD-918C-47E8-BF56-FD714D9A00B2Q39453553-9B1C2232-368C-4269-AA89-8D9A96700337Q40828834-809448FF-ED9F-475D-9B99-B1FFE903ED1BQ41340207-60C4A3CC-0F1F-447D-A6DC-C2026DFCA5C9Q41714879-B6D475F2-F6A5-4F84-A495-E370FA18AE58Q41952342-A776DB71-6903-4C37-830B-ED8160430DF0
P2860
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Level of HER2 gene amplificati ...... ncer treated with trastuzumab.
@en
Level of HER2 gene amplificati ...... ncer treated with trastuzumab.
@nl
type
label
Level of HER2 gene amplificati ...... ncer treated with trastuzumab.
@en
Level of HER2 gene amplificati ...... ncer treated with trastuzumab.
@nl
prefLabel
Level of HER2 gene amplificati ...... ncer treated with trastuzumab.
@en
Level of HER2 gene amplificati ...... ncer treated with trastuzumab.
@nl
P2093
P50
P356
P1476
Level of HER2 gene amplificati ...... ancer treated with trastuzumab
@en
P2093
Carlos Gomez-Martin
Clara Montagut
Elena Del Valle
Elena Garralda
Fernando Lopez-Rios
Fernando Rivera
Francesc Pons
Jose Carlos Plaza
Laura Visa
P304
P356
10.1200/JCO.2013.48.9070
P407
P577
2013-10-14T00:00:00Z